The WiTT Group Inc., a company focused on solving the non-clinical challenges patients face as they go through cancer treatment, formed a partnership Mary Crowley Cancer Research to identify and help patients gain access to clinical trials.
A series of preclinical studies show that a new compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma stem cells, impairing the cancer cells’ ability to survive and grow.
